Evi Comploj

Dr. Evi Comploj


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2013 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
ECEvi Comploj
Evi Comploj
CMChristine Mian
Christine Mian
Andrea Ambrosini-SpaltroAndrea Ambrosini-Spaltro
Andrea Ambrosini-Spaltro
CDChristopher Dechet
Christopher Dechet
SPSalvatore Palermo
Salvatore Palermo
APArmin Pycha
Armin Pycha
BACKGROUND: The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow‐up of patients with urothelial carcinoma.METHODS: Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years‐99 years) were enrolled in the current study. All patients seen for the follow‐up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.RESULTS: Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).CONCLUSIONS: On the basis of their 9‐year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow‐up of patients with non–muscle‐invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392–397. © 2013 American Cancer Society.

29 October 2013 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
ECEvi Comploj
Evi Comploj
CDChristopher B. Dechet
Christopher B. Dechet
MMMichael Mian
Michael Mian
ETEmanuela Trenti
Emanuela Trenti
SPSalvatore Palermo
Salvatore Palermo
APArmin Pycha
Armin Pycha

1 December 2013 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
ECEvi Comploj
Evi Comploj
WCWalburga Cassar
Walburga Cassar
AFAlessandra Farina
Alessandra Farina
PGPaolo Gasparella
Paolo Gasparella
ETEmanuela Trenti
Emanuela Trenti
APArmin Pycha
Armin Pycha

5 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
DIDafina Ilijazi
Dafina Ilijazi
WPWalter Pulverer
Walter Pulverer
IEIris Elisabeth Ertl
Iris Elisabeth Ertl
ULUrsula Lemberger
Ursula Lemberger
SKShoji Kimura
Shoji Kimura
MHMelanie Hassler
Melanie Hassler
Background: Bacillus Calmette-Guérin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecular markers to help guide responses are scarce and currently not used in the clinical setting. Methods: To identify novel biomarkers and pathways involved in response to BCG immunotherapy, we performed a genome-wide DNA methylation analysis of NMIBCs before BCG therapy. Genome-wide DNA methylation profiles of DNA isolated from tumors of 26 BCG responders and 27 failures were obtained using the Infinium MethylationEPIC BeadChip. Results: Distinct DNA methylation patterns were found by genome-wide analysis in the two groups. Differentially methylated CpG sites were predominantly located in gene promoters and gene bodies associated with bacterial invasion of epithelial cells, chemokine signaling, endocytosis, and focal adhesion. In total, 40 genomic regions with a significant difference in methylation between responders and failures were detected. The differential methylation state of six of these regions, localized in the promoters of the genes GPR158, KLF8, C12orf42, WDR44, FLT1, and CHST11, were internally validated by bisulfite-sequencing. GPR158 promoter hypermethylation was the best predictor of BCG failure with an AUC of 0.809 (p-value < 0.001). Conclusions: Tumors from BCG responders and BCG failures harbor distinct DNA methylation profiles. Differentially methylated DNA regions were detected in genes related to pathways involved in bacterial invasion of cells or focal adhesion. We identified candidate DNA methylation biomarkers that may help to predict patient prognosis after external validation in larger, well-designed cohorts.

15 July 2015 in Urologia Journal
Verified
Journal Article
Closed access
ECEvi Comploj
Evi Comploj
ETEmanuela Trenti
Emanuela Trenti
SPSalvatore Palermo
Salvatore Palermo
APArmin Pycha
Armin Pycha
CMChristine Mian
Christine Mian
Bladder carcinoma is the most common malignancy of the urinary tract and cystoscopy with cytology is currently considered the gold standard for the detection and surveillance of primary tumors and for the follow-up of patients after transurethral resection. Even if cytology has a low sensitivity especially in low-grade bladder carcinomas, the high specificity and the inexpensive nature of the equipment required, justify performing it. The greatest value of cytology for patients with low-grade, nonmuscle-invasive bladder cancer (NMIBC) is the detection of those lesions that may progress to high-grade urothelial carcinoma.

1 January 2009 in Case Reports in Dermatology
Verified
Journal Article
Open access
PDF file
ECEvi Comploj
Evi Comploj
SPSalvatore Palermo
Salvatore Palermo
ETEmanuela Trenti
Emanuela Trenti
MLMichele Lodde
Michele Lodde
CMChristine Mian
Christine Mian
APArmin Pycha
Armin Pycha
A case of primary malignant melanoma of the urethra in a 60-year-old male is presented. Despite multiple adverse prognostic factors and against expectations, after a follow-up of 5.5 years he is still alive.